Literature DB >> 7800005

Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.

J J Sung1, S C Chung, T K Ling, M Y Yung, V K Leung, E K Ng, M K Li, A F Cheng, A K Li.   

Abstract

BACKGROUND: There is a strong association between infection with Helicobacter pylori and gastric ulcers that are unrelated to the use of nonsteroidal antiinflammatory medications. We studied the efficacy of antibacterial therapy without medication to suppress gastric acid for the treatment of patients with H. pylori infection and gastric ulcers unrelated to the use of nonsteroidal agents.
METHODS: Patients with gastric ulcers seen on endoscopy and with H. pylori infection confirmed by smear or culture were randomly assigned to receive either a one-week course of antibacterial agents (120 mg of bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, each given orally four times a day) or a four-week course of omeprazole (20 mg orally per day). Follow-up endoscopies were performed after five and nine weeks. The patients and their physicians were aware of the treatment assignments, but the endoscopists were not.
RESULTS: A total of 100 patients were randomly assigned to treatment, and 85 completed the trial. At five weeks, H. pylori had been eradicated in 41 of the 45 patients in the antibacterial-treatment group (91.1 percent; 95 percent confidence interval, 82.9 to 99.3) and in 5 of the 40 in the omeprazole group (12.5 percent; 95 percent confidence interval, 2.3 to 22.7; P < 0.001). The gastric ulcers were healed in 38 of the patients treated with antibacterial drugs (84.4 percent; 95 percent confidence interval, 73.9 to 95.0) and in 29 of those treated with omeprazole (72.5 percent; 95 percent confidence interval, 58.6 to 86.4; P = 0.28). At nine weeks, ulcer healing was confirmed in 43 of the patients receiving antibacterial therapy and in 37 of those receiving omeprazole (P = 1.0). The mean (+/- SD) duration of pain during the first week of treatment was 1.9 +/- 2.6 days in the omeprazole group, as compared with 3.6 +/- 3.0 days in the antibacterial-treatment group (P = 0.004). One year after treatment, recurrent gastric ulcers were detected in 1 of 22 patients (4.5 percent) in the antibacterial-treatment group and in 12 of 23 (52.2 percent) in the omeprazole group (P = 0.001). H. pylori was detected in the 1 patient with a recurrent ulcer who had received antibacterial treatment and in 10 of the 12 patients with recurrent ulcers who had received omeprazole.
CONCLUSIONS: In patients with H. pylori infection and gastric ulcers unrelated to the use of nonsteroidal antiinflammatory drugs, one week of antibacterial therapy without acid suppression heals the ulcers as well as omeprazole and reduces the rate of their recurrence.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7800005     DOI: 10.1056/NEJM199501193320302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  46 in total

Review 1.  Treatment of Helicobacter pylori.

Authors:  A Harris
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  Helicobacter pylori heat shock protein A: serologic responses and genetic diversity.

Authors:  E K Ng; S A Thompson; G I Pérez-Pérez; I Kansau; A van der Ende; A Labigne; J J Sung; S C Chung; M J Blaser
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  Sequence analysis and clinical significance of the iceA gene from Helicobacter pylori strains in Japan.

Authors:  Y Ito; T Azuma; S Ito; H Suto; H Miyaji; Y Yamazaki; T Kato; Y Kohli; Y Keida; M Kuriyama
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

4.  Antacid effects of Chinese herbal prescriptions assessed by a modified artificial stomach model.

Authors:  Tsung-Hsiu Wu; I-Chin Chen; Lih-Chi Chen
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

5.  iceA genotypes of Helicobacter pylori strains isolated from Brazilian children and adults.

Authors:  A A Ashour; G B Collares; E N Mendes; V R de Gusmão; D M Queiroz; P P Magalhães; A S de Carvalho; C A de Oliveira; A M Nogueira; G A Rocha; A M Rocha
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

6.  Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.

Authors:  Ping-I Hsu; Feng-Woei Tsai; Sung-Shuo Kao; Wen-Hung Hsu; Jin-Shiung Cheng; Nan-Jing Peng; Kuo-Wang Tsai; Huang-Ming Hu; Yao-Kuang Wang; Seng-Kee Chuah; Angela Chen; Deng-Chyang Wu
Journal:  Am J Gastroenterol       Date:  2017-07-18       Impact factor: 10.864

7.  Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection.

Authors:  Takeshi Hagiwara; Mototsugu Kato; Tomonori Anbo; Akimichi Imamura; Toshihiro Suga; Takumi Uchida; Akira Fujinaga; Manabu Nakagawa; Soichi Nakagawa; Yuichi Shimizu; Jyunji Yamamoto; Hiroshi Takeda; Masahiro Asaka
Journal:  World J Gastroenterol       Date:  2007-07-28       Impact factor: 5.742

8.  [1997 gastroenterology update--I].

Authors:  W Fischbach; S S Gro; J Schölmerich; C Ell; P Layer; W E Fleig; H Zirngibl
Journal:  Med Klin (Munich)       Date:  1998-02-15

9.  Effect of glycine on Helicobacter pylori in vitro.

Authors:  Masaaki Minami; Takafumi Ando; Shin-Nosuke Hashikawa; Keizo Torii; Tadao Hasegawa; Dawn A Israel; Kenji Ina; Kazuo Kusugami; Hidemi Goto; Michio Ohta
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 10.  Helicobacter pylori: present status and future prospects in Japan.

Authors:  Hidekazu Suzuki; Toshifumi Hibi; Barry James Marshall
Journal:  J Gastroenterol       Date:  2007-02-16       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.